Understand the source comparison
Best Peptides for Chronic Inflammation: Mechanism Comparison
The following table compares the best peptides for chronic inflammation by mechanism, evidence base, and typical research dosing protocols used in published studies. BPC-157 VEGFR2 agonism, angiogenesis promotion, NF-κB modulation NF-κB translocation, oxidativ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the best peptides for chronic inflammation by mechanism, evidence base, and typical research dosing protocols used in published studies.
- BPC-157
- VEGFR2 agonism, angiogenesis promotion, NF-κB modulation
- NF-κB translocation, oxidative stress, endothelial dysfunction
- 200–500 mcg daily subcutaneous
- Extensive preclinical; no Phase III human trials
- Best-studied for tissue repair and localized inflammation in musculoskeletal models
- Thymosin Alpha-1
- T-cell differentiation, TLR signaling enhancement, IFN-α production
- Immune exhaustion, chronic viral inflammation, T-cell dysfunction
- 1.6 mg twice weekly subcutaneous
- Meta-analyses in hepatitis; Phase III trials outside U.S.
- Strongest evidence for immune-driven chronic inflammation and infection-related states
- TB-500
- Actin binding, fibroblast regulation, anti-fibrotic signaling
- Fibrosis, myofibroblast differentiation, extracellular matrix remodeling
- 2–10 mg twice weekly subcutaneous
- Preclinical cardiac and musculoskeletal models
- Best anti-fibrotic option for preventing scar tissue in chronic injury states
- KPV
- Intracellular NF-κB inhibition (nuclear translocation blockade)
- NF-κB pathway, cytokine gene transcription, mucosal inflammation
- 500 mcg–2 mg daily oral or subcutaneous
- Preclinical colitis and dermatitis models
- Most direct NF-κB inhibitor; oral bioavailability makes it unique for GI inflammation
- LL-37
- LPS binding, TLR4 inhibition, keratinocyte migration
- Endotoxin-mediated inflammation, wound healing, antimicrobial defense
- Variable (topical or subcutaneous, dose-dependent on condition)
- Preclinical sepsis and wound models
- Best for infection-driven inflammation and barrier tissue repair (skin, mucosa)